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The Beta-Fibrinogen 455 G/A Polymorphism genotype and allel frequencies
AF patients with
Ischemic Stroke
(n:70)
Control
(n:65)
n: % n: %
GG genotype 23 32.9 36 55.4 0.008
GA genotype 27 38.6 25 38.5 0.990
AA genotype 20 28.6 4 6.2 0.001
GA+ AA genotypes
(Dominant genetic
model)
47 67.1 29 44.6 0.008
A allel 67 47.8 33 25.3 0.001
O
R
A
L
SOP-150
Novel Fibroinﬂammatory Markers in Non-valvular Atrial Fibrillation:
Galectin-3, Lcn2/NGAL, P3NP
Osman Sonmez1, Furkan U Ertem2, Mehmet Akif Vatankulu1, Ercan Erdogan1,
Abdurrahman Tasal1, Sıtkı Kucukbuzcu1, Omer Goktekin1
1BezmiAlem Vakif University, Faculty of Medicine, Department of Cardiology,
Istanbul, 2Istanbul University Istanbul Faculty of Medicine, Istanbul
Introduction: Atrial ﬁbrillation is the most common cardiac arrhythmia increasing
the risk of stroke and death. Inﬂammation is an important factor involved in the
initiation, maintenance and recurrence of AF and The abnormal inﬂammatory state
may also cause a prothrombotic state resulting thromboembolism. In the present study
we aim to investigate whether serum levels of galectin-3, Matrix Metalloproteinase 9
(MMP-9) and Procollagen III N-Terminal Propeptide (PIIINP),Human Lipocalin-2/
NGAL and NLR differ in patients with AF compared to patients with sinus rhythm in
the guidance of serum levels of MMP-9 and Hs-CRP. We also evaluated associations
of these markers with atrial structural remodeling which was interpreted by measuring
the left atrial volume index.
Methods: The study population included 85 patients who were seen in our outpa-
tient clinic between March 2012 and January 2012. 52 patients who diagnosed with
non-valvular AF recruited into AF group. End-stage hepatic or renal disease,
malignancy, any prior blood transfusions, carotid artery disease, prior transient
ischemic attack, ischemic or hemorrhagical stroke and oral anticoagulant usage were
exclusion criteria in our study. 35 age-matched patients with sinus rhythm recruited
into control group. Serum levels of Galectin-3, Matrix Metalloproteinase 9 (MMP-9)
and Procollagen III N-Terminal Propeptide (PIIINP) were measured by using
a commercial enzyme-linked immunoassay kits and each assay was carried out in
duplicate. Galectin-3, NGAL, MMP-9 and PIIINP levels were measured by using
sandwich ELISA (Human Galectin-3 ELISA kit, eBioscience; Lipocalin-2/NGAL
Elisa kit, BioVendor Research and Diagnostic Products; Human Matrix Metal-
loproteinase 9, Bio-Medical Assay; Human Procollagen III N-Terminal Propeptid,
Bio-Medical Assay).
Results: There were signiﬁcant differences between the groups in terms of
inﬂammatory and remodeling markers except NGAL levels. We showed signiﬁ-
cantly higher levels of Galectin-3, MMP-9, PIIINP in in NVAF group compared to
control group (1166 pg/ml (1126-1204) & 1204 pg/ml (1166-1362) p¼0.001
Mann-Whitney U test, 14688 pg/ml & 429302 pg/ml p<0.0001 Student-t test,
and 1426Student-t test respectively). Hs1230 pg/ml & 65904594 pg/ml
p<0.0001 -Crp and NLR level were also higher in NVAF (2.11.0 & 2.71.1
p¼0.02 Student-t test and 4.21.9 mg/L & 6.04.7 mg/L p¼0.04 Student-t test,
respectively).
In correlation analyses, NLR showed quite signiﬁcant correlation with LAVi
whereas Hs-CRP did not (p¼0.007 r¼0.247, pearson test & p¼0.808 r¼0.025,
pearson test,respectively). Moreover, Galectin-3, MMP-9, and PIIINP had strong
positive correlation with LAVi (p¼0.021 r¼640, spearman test & p¼0.004 r¼0.319
pearson test, & p¼0.004 r¼0.325 pearson test,respectively).
Conclusion: As a result of this data we suggest that galectin-3 and PIIINP can be used
as novel targets in AF patients in order to decrease degree of ﬁbro-inﬂammation in
the atria.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORAOP-151
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Background: Atrial ﬁbrillation (AF) is the most commonly observed arrhythmia in
clinical practice and associated with increased cardiovascular morbidity and
mortality. Compared to healthy population, nonvalvular AF has a 2-7 fold
increased risk of ischemic stroke. The mechanisms of thrombus formation in AF
are still investigated. Fibrinogen plays an active role during the coagulation
process. Increased plasma ﬁbrinogen levels were shown to be associated with
the coronary heart disease, peripheral artery disease and venous thrombosis.
Beta-ﬁbrinogen 455 G/A polymorphism is a gene mutation that may lead to
alterations in the activity of ﬁbrinogen. We wanted to investigate Beta-ﬁbrinogen
455 G/A polymorphism in patients with AF who have had a stroke than in healthy
controls.
Methods: The Beta-ﬁbrinogen 455 G/A polymorphism was analysed in 70 patients
with AF who have had a stroke 65 healthy individuals matched for age, race and sex.
Because ethnic differences have been reported for Beta-ﬁbrinogen 455 G/A poly-
morphism. The Beta-ﬁbrinogen 455 G/A gene polymorphism was identiﬁed by
polymerase chain reaction (PCR) method. Distribution of the Beta-ﬁbrinogen 455 G/A
gene polymorphism alles (allel G, allel A) genotypes (Normal (GG) genotype,
heterozygous (GA) or homozygous (AA) mutant genotype) were identiﬁed in study
population. Demographic characteristics and risk factors for AF and stroke were
evaluated in the study groups.
Results: There was no signiﬁcant difference with respect to age and gender between
groups. Genotype and allel distribution of nonvalvular AF patients with ischemic
stroke and control groups shown in the table. The frequency of GG genotype of Beta-
ﬁbrinogen 455 G/A polymorphism was signiﬁcantly lower in patients with AF who
have had a stroke group compared with control group (p<0,05). The frequency of GA
heterozygous genotype was similar between groups. The frequency of AA homozy-
gous mutant genotype of Beta-ﬁbrinogen 455 G/A polymorphism was signiﬁcantly
higher in patients with AF who have had a stroke group compared with control group
(p<0,05). Between the two groups were compared according to the dominant genetic
model (GA+AA vs. GG), The number of patients carrying at least one A mutant
allele (GA+AA) were signiﬁcantly higher in patients with AF who have had a stroke
group than controls (p<0,05). With respect to allelic distribution (G vs A, additive
model), the frequency of the A mutant allele was signiﬁcantly higher in CAE patients
(p<0,05).
Conclusions: In this study, we found that the frequency of b-ﬁbrinogen 455 G/A gene
polymorphism was higher in patients with AF who have had a stroke group compared
to control subject. However, further large-sized studies are required for determining
relationship between b-ﬁbrinogen 455 G/A gene polymorphisms and patients with AF
who have had a stroke group.LS C67
